View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Tile Shop Announces Special Meeting Results, Stock Split Ratio and Int...

Tile Shop Announces Special Meeting Results, Stock Split Ratio and Intention to Delist from Nasdaq MINNEAPOLIS, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Tile Shop Holdings, Inc. (Nasdaq: TTSH) (“Tile Shop” or the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles, setting and maintenance materials and related accessories, today announced that, at the special meeting of stockholders of the Company held on December 3, 2025 (the “Special Meeting”), the requisite stockholders of the Company approved an amendment to the certificate of incorporation of the Company, as a...

 PRESS RELEASE

The Tile Shop Expands Exclusive Collaboration With Designer Kelli Font...

The Tile Shop Expands Exclusive Collaboration With Designer Kelli Fontana, Adds New Patterned and Porcelain Tile Designs MINNEAPOLIS, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The Tile Shop, the Minnesota-based specialty retailer of natural stone and man-made tiles, today announced new additions to its exclusive collaboration with designer Kelli Fontana, expanding one of the retailer’s top-performing designer collections. Following strong customer demand for standout Kelli Fontana styles like —the company’s current #1 best-selling patterned tile—the new and designs offer fresh opportunities f...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

 PRESS RELEASE

Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcar...

Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th DEER PARK, Ill., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team, will host a fireside chat at the Piper Sandler 37th Annual Healthcare Conference being held in NYC as follows: DATE: Thursday, December 4, 2025 TIME: 9:30AM ETLOCATION: Lotte New York Palace To...

 PRESS RELEASE

Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha ...

Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th DEER PARK, Ill., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1x1 meetings at the 16th Annual Craig-Hallum Alpha Select Conference being held November 18, 2025 in New York, NY. To schedule a 1x1 meeting with the Company, please contact your ...

 PRESS RELEASE

Certara Reports Third Quarter 2025 Financial Results

Certara Reports Third Quarter 2025 Financial Results  Updates Full Year 2025 Financial Guidance RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025. Third Quarter Highlights: Revenue was $104.6 million, compared to $94.8 million in the third quarter of 2024, representing growth of 10%. Software revenue was $43.8 million, compared to $35.9 million in the third quarter of 2024, representing growth of 22%.Services revenue was $60.8 m...

 PRESS RELEASE

Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results

Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results Q3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and 19th straight quarter of sequential product sales growthQ3 2025 basic and fully diluted GAAP EPS of $(0.07), non-GAAP fully diluted EPS of $0.04, and Adjusted EBITDA of $2.9 millionET-600 NDA accepted for review, assigned PDUFA date of February 25, 2026GALZIN® launch ahead of plan; exceeded previous year-end target of 200 active patientsHeld positive FDA meeting clarifying pathway to KHINDIVI™ label expansionSubmitted proposed clinical study to ...

 PRESS RELEASE

The Tile Shop Reports Third Quarter 2025 Results

The Tile Shop Reports Third Quarter 2025 Results MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles, today announced results for its third quarter ended September 30, 2025. Third Quarter 2025 Summary Net Sales Decreased 1.7%Comparable Store Sales Decreased 1.4% Gross Margin of 62.9%Net Loss of $1.6 Million and Adjusted EBITDA of $2.0 MillionNo Debt Outstanding and $24.1 million of Cash at Quarter-End Management Commentary – Cabell Lolmaugh, CEO “Unit volumes inc...

 PRESS RELEASE

Certara Automates Scientific Workflows with Phoenix® Cloud

Certara Automates Scientific Workflows with Phoenix® Cloud New cloud capabilities cut time to create Tables, Figures, and Listings by 50% RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module of its Phoenix Cloud solution. TFLs (Tables, Figures, and Listings) present data on study participants, treatments, and outcomes visually for clear interpretation. They are critical components of regulatory submissions and scientific publications. TFL St...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: November 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Certara to Participate in Upcoming Investor Conferences

Certara to Participate in Upcoming Investor Conferences RADNOR, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: UBS Global Healthcare ConferenceDate and Time: Tuesday, November 11th 2025 at 2:00PM ET Jefferies Global Healthcare Conference in LondonDate and Time: Tuesday, November 18th 2025 at 10:30AM GMT Stephens Annual Investment ConferenceDate and Time: Tuesday, November 18th 2025 at 1:00PM CT Live webcasts for each ...

 PRESS RELEASE

The Tile Shop to Report Third Quarter 2025 Financial Results

The Tile Shop to Report Third Quarter 2025 Financial Results MINNEAPOLIS, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles, setting and maintenance materials and related accessories, today announced that the Company will release financial results for the third quarter ended September 30, 2025 on Tuesday November 4, 2025, after the close of the financial markets. The Company will not be hosting a conference call.   The Company intends to use its website, , as a means of disclos...

 PRESS RELEASE

Certara Expands Biosimulation Market with AI-Driven QSP Platform

Certara Expands Biosimulation Market with AI-Driven QSP Platform Certara IQ™ integrates AI and biosimulation to accelerate R&D productivity, reduce risk, and deepen understanding of novel and complex therapies RADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara IQ, a scalable, AI-powered Quantitative Systems Pharmacology (QSP) solution. QSP has rapidly become a cornerstone of modern drug discovery and development with QSP-based FDA submissions having nearly doubled every 1...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 25, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on...

Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 DEER PARK, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Participant Call Link:Webcast:   In addition to ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 22, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Certara Scientists are Among the Topmost Cited Biopharma Researchers

Certara Scientists are Among the Topmost Cited Biopharma Researchers Certara celebrates its 200 published papers and 11 scientists on Stanford/Elsevier top 2% cited researchers list in 2025 RADNOR, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its continued influence in pharmaceutical research. With more than 200 papers authored by Certara scientists* this past year and 11 Certara scientists included on the  of the top 2% most cited scientists across the globe, Certara’s powerhouse of scientific k...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 18, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

After 5.5-months, the S&P 500 (SPX) finally broke below its 20-day MA in decisive fashion on Friday. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay that way as long as the SPX holds abov...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch